Our process is physician-led at every stage and directed at strategic value from the first meeting. What follows is how we work with a company, from the first conversation through to a strategic outcome.
Every stage asks the same question: what must be true for this company to matter to the acquirer who will eventually own the category? The path is not strictly linear. A company can become relevant to a buyer at several of these points, not only at the end.
Our deal flow comes through a national network of practising cardiologists and electrophysiologists. The clinicians who encounter the problems first are the ones who surface the technologies.
The specialists who would actually use the technology assess it across different operators, procedure volumes, and practice settings.
We sharpen the indication, the evidence plan, and the positioning. This often surfaces value the original team had not identified.
Capital-efficient company-building that preserves ownership and answers the next strategic question a buyer will ask.
Where a company goes to market, we support workflow integration, physician adoption, and the commercial groundwork between clearance and scale.
We engineer strategic optionality from the first day, so a company is acquisition-ready and positioned for the buyers most likely to own the category. That readiness is built throughout, not reserved for the end.
Our diligence is built to set aside marketing narrative and founder optimism and establish what is actually true about a technology, its market, and its likely buyers.
Specialist cardiologists and electrophysiologists evaluate the technology against real workflows, real operators, and the institutional barriers to adoption, rather than the published data alone.
We examine regulatory status, evidence sufficiency, and reimbursement logic document by document. Every material claim in our internal memos carries its source.
We ask which acquirer the company should matter to, what would make them care, and what must be true for them to act. Then we test that answer rather than assume it.
Share non-confidential materials through our founder submission form. We do not sign NDAs prior to an initial review, and every submission is read.
If there is a potential fit, the technology goes in front of the specialists who would actually use it. You will hear their candid assessment, and that candor is the value we add.
We map the indication, the evidence plan, and the positioning against where the strategic acquirers in the category are actually moving.
If the conviction is there, we discuss structure: physician-led, acquisition-oriented capital, and an ecosystem that works alongside you from the earliest stages.
We start with who you are and what you are looking for. Participation is limited to accredited investors, and any offering is made only through definitive documents.
Qualified investors receive the work behind our conviction: the clinical evaluation and the strategic thesis for each opportunity, deal by deal.
NuPulse syndicates through SPVs. You decide on each deal, on institutional terms, investing alongside the physician network that evaluated the technology.
Executed documents are handled electronically, and investors receive structured updates and annual tax reporting for each vehicle.
We welcome conversations with founders, investors, physicians, and strategic partners in cardiovascular and electrophysiology medtech.
Email usMiami, Florida